{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T14:11:58Z","timestamp":1767276718956,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"crossref","award":["04R\/2016"],"award-info":[{"award-number":["04R\/2016"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["PS15\/05"],"award-info":[{"award-number":["PS15\/05"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["HRYD-030"],"award-info":[{"award-number":["HRYD-030"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Verein Zusammen gegen den Krebs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For most acute myeloid leukemia (AML) patients, an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of sustained remissions and long-term survival. At diagnosis, high expression of the AML-associated genes<jats:italic>BAALC<\/jats:italic>(brain and acute leukemia, cytoplasmic) and<jats:italic>MN1<\/jats:italic>(meningioma-1) were repeatedly linked to inferior outcomes in patients consolidated with chemotherapy while data for patients receiving HSCT remain limited. Using clinically applicable digital droplet PCR assays, we analyzed the diagnostic<jats:italic>BAALC\/ABL1<\/jats:italic>and<jats:italic>MN1\/ABL1<\/jats:italic>copy numbers in 302 AML patients. High<jats:italic>BAALC\/ABL1<\/jats:italic>and<jats:italic>MN1\/ABL1<\/jats:italic>copy numbers associated with common adverse prognostic factors at diagnosis. However, while high diagnostic copy numbers of both genes associated with shorter event free survival (EFS) and overall survival (OS) in patients receiving chemotherapy, there was no prognostic impact in patients undergoing HSCT. Our data suggests that the adverse prognostic impact of high<jats:italic>BAALC<\/jats:italic>and<jats:italic>MN1<\/jats:italic>expression are mitigated by allogeneic HSCT. But preHSCT<jats:italic>BAALC<\/jats:italic>\/<jats:italic>ABL1<\/jats:italic>and<jats:italic>MN1<\/jats:italic>\/<jats:italic>ABL1<\/jats:italic>assessed in remission prior to HSCT remained prognosticators for EFS and OS independent of the diagnostic expression status. Whether allogeneic HSCT may improve survival for AML patients with high diagnostic<jats:italic>BAALC<\/jats:italic>or<jats:italic>MN1<\/jats:italic>expression should be investigated prospectively and may improve informed decisions towards individualized consolidation options in AML.<\/jats:p>","DOI":"10.1007\/s00277-020-04235-8","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T22:02:26Z","timestamp":1598738546000},"page":"2417-2427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML"],"prefix":"10.1007","volume":"99","author":[{"given":"Madlen","family":"Jentzsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius","family":"Bill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Backhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoline","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-2332","authenticated-orcid":false,"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"4235_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"4235_CR2","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus- tumor effects. Blood 97:3390\u20133400","journal-title":"Blood"},{"key":"4235_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555\u2013562","journal-title":"Blood"},{"key":"4235_CR4","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2006-04-014845","volume":"108","author":"M Heuser","year":"2006","unstructured":"Heuser M, Beutel G, Krauter J, D\u00f6hner K, von Neuhoff N, Schlegelberger B et al (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898\u20133905","journal-title":"Blood"},{"key":"4235_CR5","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/leu.2011.228","volume":"26","author":"M Heuser","year":"2012","unstructured":"Heuser M, Berg T, Kuchenbauer F, Lai CK, Park G, Fung S et al (2012) Functional role of BAALC in leukemogenesis. Leukemia 26:532\u2013536","journal-title":"Leukemia"},{"key":"4235_CR6","first-page":"1051","volume":"31","author":"CD Baldus","year":"2003","unstructured":"Baldus CD, Tanner SM, Kusewittb DF, Liyanarachchi S, Choi C, Caligiuri MA et al (2003) BAALC, a novel marker of human hematopoietic progenitor cells. Exp Hematol 31:1051\u20131056","journal-title":"Exp Hematol"},{"key":"4235_CR7","doi-asserted-by":"publisher","first-page":"13901","DOI":"10.1073\/pnas.241525498","volume":"98","author":"SM Tanner","year":"2001","unstructured":"Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K et al (2001) BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A 98:13901\u201313906","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4235_CR8","first-page":"783","volume":"48","author":"RH Lekanne Deprez","year":"1991","unstructured":"Lekanne Deprez RH, Groen NA, van Biezen NA, Hagemeijer A, van Drunen E, Koper JW et al (1991) A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene. Am J Hum Genet 48:783\u2013790","journal-title":"Am J Hum Genet"},{"key":"4235_CR9","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1182\/blood-2007-11-124958","volume":"111","author":"C Langer","year":"2008","unstructured":"Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mr\u00f3zek K et al (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111:5371\u20135379","journal-title":"Blood"},{"key":"4235_CR10","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1182\/blood-2010-06-290536","volume":"116","author":"S Schwind","year":"2010","unstructured":"Schwind S, Marcucci G, Maharry K, Radmacher MD, Mr\u00f3zek K, Holland KB et al (2010) BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 116:5660\u20135669","journal-title":"Blood"},{"key":"4235_CR11","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1182\/blood-2011-06-357764","volume":"118","author":"S Schwind","year":"2011","unstructured":"Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mr\u00f3zek K, Maharry K et al (2011) Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 118:4188\u20134198","journal-title":"Blood"},{"key":"4235_CR12","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1200\/JCO.2008.20.5328","volume":"27","author":"KH Metzeler","year":"2009","unstructured":"Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A et al (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031\u20135038","journal-title":"J Clin Oncol"},{"key":"4235_CR13","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2008.20.6110","volume":"27","author":"C Langer","year":"2009","unstructured":"Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P et al (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 27:3198\u20133204","journal-title":"J Clin Oncol"},{"key":"4235_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1182\/blood-2003-02-0359","volume":"102","author":"CD Baldus","year":"2003","unstructured":"Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G et al (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood 102:1613\u20131618","journal-title":"Blood"},{"key":"4235_CR15","doi-asserted-by":"publisher","first-page":"87944","DOI":"10.18632\/oncotarget.21322","volume":"8","author":"M Jentzsch","year":"2017","unstructured":"Jentzsch M, Bill M, Grimm J, Schulz J, Goldmann K, Beinicke S et al (2017) High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. Oncotarget. 8:87944\u201387954","journal-title":"Oncotarget."},{"key":"4235_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000167","volume":"3","author":"M Jentzsch","year":"2019","unstructured":"Jentzsch M, Bill M, Grimm J, Schulz J, Beinicke S, H\u00e4ntschel J et al (2019) Prognostic impact of blood MN1 copy numbers before allogeneic stem cell transplantation in patients with acute myeloid leukemia. HemaSphere 3:e167","journal-title":"HemaSphere"},{"key":"4235_CR17","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1038\/bcj.2013.71","volume":"4","author":"S Weber","year":"2014","unstructured":"Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C et al (2014) BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia. Blood Cancer J 4:e173","journal-title":"Blood Cancer J"},{"key":"4235_CR18","first-page":"636","volume":"91","author":"Y Najima","year":"2010","unstructured":"Najima Y, Ohashi K, Kawamura M, Onozuka Y, Yamaguchi T, Akiyama H et al (2010) Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia. J Hematol 91:636\u2013645","journal-title":"J Hematol"},{"key":"4235_CR19","doi-asserted-by":"publisher","first-page":"74082","DOI":"10.18632\/oncotarget.12269","volume":"7","author":"S Carturan","year":"2016","unstructured":"Carturan S, Petiti J, Rosso V, Calabrese C, Signorino E, Bot-Sartor G et al (2016) Variable but consistent pattern of meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. Oncotarget 7:74082\u201374096","journal-title":"Oncotarget"},{"issue":"8","key":"4235_CR20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00277-018-3331-8","volume":"97","author":"J Zhang","year":"2018","unstructured":"Zhang J, Shi J, Zhang G, Zhang X, Yang X, Yang S et al (2018) BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol 97(8):1391\u20131397","journal-title":"Ann Hematol"},{"key":"4235_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nmeth.2633","volume":"10","author":"CM Hindson","year":"2013","unstructured":"Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ et al (2013) Absolute quantification by droplet digital PCR versus analog real- time PCR. Nat Methods 10:1003\u20131005","journal-title":"Nat Methods"},{"key":"4235_CR22","doi-asserted-by":"publisher","unstructured":"Jentzsch M, Bill M, Grimm J, Schulz J, Schuhmann L, Brauer D et al (2020) High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+\/CD38- population. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.229260","DOI":"10.3324\/haematol.2019.229260"},{"key":"4235_CR23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/bmt.2017.42","volume":"52","author":"M Bill","year":"2017","unstructured":"Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M et al (2017) Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning. Bone Marrow Transplant 52:932\u2013935","journal-title":"Bone Marrow Transplant"},{"key":"4235_CR24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41409-018-0413-0","volume":"54","author":"J Grimm","year":"2019","unstructured":"Grimm J, Bill M, Jentzsch M, Beinicke S, H\u00e4ntschel J, Goldmann K et al (2019) Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation. Bone Marrow Transplant 54:1189\u20131197","journal-title":"Bone Marrow Transplant"},{"key":"4235_CR25","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2017","unstructured":"R Core Team (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna http:\/\/www.R-project.org"},{"key":"4235_CR26","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","volume":"26","author":"DA Breems","year":"2008","unstructured":"Breems DA, van Putten WLJ, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791\u20134797","journal-title":"J Clin Oncol"},{"key":"4235_CR27","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/1078-0432.CCR-04-1552","volume":"11","author":"M Bienz","year":"2005","unstructured":"Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M et al (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11:1416\u20131424","journal-title":"Clin Cancer Res"},{"key":"4235_CR28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2005.01.6253","volume":"24","author":"CD Baldus","year":"2006","unstructured":"Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G (2006) BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 24:790\u2013797","journal-title":"J Clin Oncol"},{"key":"4235_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2162-3619-2-7","volume":"2","author":"J Brand","year":"2013","unstructured":"Brand J, van Vliet MH, de Best L, Valk PJ, Vi\u00ebtor HE, L\u00f6wenberg B et al (2013) A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. Exp Hematol Oncol 2:7","journal-title":"Exp Hematol Oncol"},{"key":"4235_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00277-009-0864-x","volume":"89","author":"C Santamar\u00eda","year":"2010","unstructured":"Santamar\u00eda C, Chill\u00f3n MC, Garc\u00eda-Sanz R, P\u00e9rez C, Caballero MD, Mateos MV et al (2010) BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol 89:453\u2013458","journal-title":"Ann Hematol"},{"key":"4235_CR31","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.23516","volume":"88","author":"D Damiani","year":"2013","unstructured":"Damiani D, Tiribelli M, Franzoni A, Michelutti A, Fabbro D, Cavallin M et al (2013) BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. Am J Hematol 88:848\u2013852","journal-title":"Am J Hematol"},{"key":"4235_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/gcc.20950","volume":"51","author":"C Haferlach","year":"2012","unstructured":"Haferlach C, Kern W, Schindela S, Kohlmann A, Alpermann T, Schnittger S et al (2012) Gene expression of BAALC, CDKNIB, ERG and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia. Genes Chromosom Cancer 51:257\u2013265","journal-title":"Genes Chromosom Cancer"},{"key":"4235_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3109\/10428194.2013.800869","volume":"55","author":"JH Yoon","year":"2014","unstructured":"Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS et al (2014) Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. Leuk Lymphoma 55:110\u2013120","journal-title":"Leuk Lymphoma"},{"key":"4235_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/leu.2009.272","volume":"24","author":"T Liu","year":"2010","unstructured":"Liu T, Jankovic D, Brault L, Ehret S, Baty F, Stavropoulou V et al (2010) Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia 24:601\u2013512","journal-title":"Leukemia"},{"issue":"9","key":"4235_CR35","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15(9):986\u2013996","journal-title":"Lancet Oncol"},{"key":"4235_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbmt.2015.10.023","volume":"22","author":"AD Ho","year":"2016","unstructured":"Ho AD, Schetelig J, Bochtler T, Schaich M, Sch\u00e4fer-Eckart K, H\u00e4nel M et al (2016) Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. Biol Blood Marrow Transplant 22:462\u2013469","journal-title":"Biol Blood Marrow Transplant"},{"key":"4235_CR37","doi-asserted-by":"crossref","unstructured":"Grimm J, Jentzsch M, Bill M et al (2020) Prognostic Impact of the European LeukemiaNet 2017 risk classification in acute myeloid leukemia patients receiving allogeneic transplantation. Blood Adv In Press","DOI":"10.1182\/bloodadvances.2020001904"},{"key":"4235_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y et al (2016) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease\u2013based definition of complete remission? J Clin Oncol 34:329\u2013336","journal-title":"J Clin Oncol"},{"key":"4235_CR39","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB et al (2016) Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 30:1456\u20131464","journal-title":"Leukemia"},{"key":"4235_CR40","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C et al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132:1703\u20131713","journal-title":"Blood"},{"key":"4235_CR41","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","volume":"97","author":"M Bill","year":"2018","unstructured":"Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J et al (2018) Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol 97:1757\u20131765","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04235-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04235-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T03:12:14Z","timestamp":1668136334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04235-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4235"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04235-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}